MURA

Mural Oncology Plc Completes Acquisition by XRA 5 Corp.

PremiumCompany Announcements

19d ago

Mural Oncology announces effectiveness of scheme of arrangement

PremiumThe Fly

19d ago

Mural Oncology announces final cash consideration payable on acquisition close

PremiumThe Fly

28d ago

Mural Oncology Approves Acquisition by XRA 5 Corp.

PremiumCompany Announcements

2M ago

PremiumThe FlyMural Oncology shareholders approve acquisition by XRA 5 Corp.

2M ago

Company Announcements

Mural Oncology Plc Announces Acquisition by XOMA Royalty Corporation

3M ago

Company Announcements

Mural Oncology Plc Announces Acquisition Agreement

4M ago

Mural Oncology PLC trading resumes

PremiumThe Fly

4M ago

Mural Oncology to be acquired by XRA 5 Corp. for $2.035-$2.24 per share in cash

PremiumThe Fly

4M ago

Mural Oncology PLC trading halted, news pending

PremiumThe Fly

4M ago

Mural Oncology reports Q2 EPS ($2.78) vs ($1.86) last year

PremiumThe Fly

5M ago

PremiumCompany AnnouncementsMural Oncology Plc Elects Directors at Annual Meeting

7M ago

Pre-Earnings

MURA Upcoming Earnings Report: What to Expect?

7M ago

Largest borrow rate increases among liquid names

Unusually active option classes on open April 21st

The Fly

Largest borrow rate increases among liquid names

8M ago

QID

AISP

PremiumThe Fly

8M ago

AMC

PremiumThe Fly

Mural Oncology to discontinue nemvaleukin development, reduce staff by 90%

8M ago

Mural Oncology plans to explore strategic alternatives

PremiumThe Fly

8M ago

Mural Oncology price target lowered to $6 from $18 at H.C. Wainwright

PremiumThe Fly

9M ago

PremiumThe FlyMural Oncology halting progress of nemvaleukin trial in ovarian cancer

9M ago

MRK

The Fly

Mural Oncology downgraded to Hold from Buy at JonesResearch

9M ago

The Fly

Mural Oncology downgraded to Outperform from Strong Buy at Raymond James

9M ago